The abstract is read at the publisher; the summary is JClub's.
In multiple myeloma cells, PP1C dephosphorylates KRAS/NRAS T148 to enable LZTR1-dependent proteasomal degradation, while KRAS A146 gain-of-function mutations resist this pathway.
- Why it matters: RAS signaling in hematologic malignancies is less defined than in carcinomas, and blood-cancer–specific control of RAS protein stability could reveal actionable vulnerabilities.
- What they did: Using multiomics screens, the study mapped T148 phosphorylation control by PP1C and showed that PAK1/2 protect RAS from LZTR1-mediated degradation by phosphorylating T148.
- The result: KRAS protein stability was 4-fold lower in hematologic versus carcinoma cells, and inhibiting PAK1/2 increased RAS-directed therapy efficacy in multiple myeloma, with KRAS A146 shielding degradation in DLBCL and AML.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.